Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma

Yutaka Takeda, Shoji Nakamori, Hidetoshi Eguchi, Shogo Kobayashi, Shigeru Marubashi, Masahiro Tanemura, Koji Konishi, Yasuo Yoshioka, Koji Umeshita, Masaki Mori, Yuichiro Doki, Hiroaki Nagano

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)

Abstract

Objective: We report the response to pre-operative gemcitabine-based chemoradiotherapy for pancreatic adenocarcinoma. Methods: Thirty-five consecutive patients with borderline resectable pancreatic adenocarcinoma of UICC Stage II or III with portal vein invasion or tumor abutment of artery received radiotherapy (twice daily fractions of 1.5 Gy, 5 days/week, total dose: 36 Gy; 30 Gy for Phase I Level 1) with weekly intravenous infusions of gemcitabine (400, 600 and 800 mg/m2) at Days 1 and 8 forPhase I and 800 mg/m2 for Phase II. Restaging was repeated after completion of chemoradiotherapy. Results: Twenty-six of the 35 (74.3%) patients underwent resection. The dose-limiting toxicities were Grade 4 neutropenia and thrombocytopenia. The recommended regimen was total radiation dose of 36 Gy with gemcitabine 800 mg/m2. Surgical resection was conducted in 11 of the 15 (73.3%) patients in Phase I study and 15 of the 20 (75.0%) in Phase II. After recommended dose chemoradiotherapy and surgical resection, the median disease-free survival was 17.4 months (5-year survival rate = 14.3%). The median overall survival time and 5-year survival rate were 41.2 months and 28.6%, respectively, for the 21 patients who underwent resection and 10.0 months and 0%, respectively, for those 5 who did not (P = 0.004). Conclusion: Our pre-operative gemcitabine-based chemoradiotherapy was well tolerated and safe.

Original languageEnglish
Pages (from-to)1172-1180
Number of pages9
JournalJapanese journal of clinical oncology
Volume44
Issue number12
DOIs
Publication statusPublished - Dec 1 2014

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this